Kornimate/medical-research-clean huggingface dataset:
bilateral benefit in adult users of the hires 90k bionic ear system

Conditions: Hearing Loss

Summary: normal hearing listeners gain important everyday benefits from listening with two ears (bilateral hearing) compared to their baseline performance with hearing aids. advantages of bilateral hearing include the ability to determine where sounds are coming from and the ability to hear sounds and understand speech in noisy environments. based upon these advantages, this study will (1) evaluate the benefit of hearing with two bionic ear implants (one in each ear) and (2) compare hiresolution sound processing with conventional sound processing.


Eligibility criteria:
inclusion criteria: 1. no previous implant experience. 2. age 18 years or older. 3. postlingual onset of hearing loss. 4. sensorineural hearing loss of a severe or greater degree in both ears. 5. normal/patent cochlear anatomy in each ear. 6. english language proficiency. 7. willingness and ability to participate in all scheduled procedures. exclusion criteria: no exclusion criteria specified, except for the opposite of inclusion criteria listed above.

Keywords: hiresolution bionic ear severe to profound hearing loss bilateral implantation
effect of androgen deprivation therapy on cardiovascular function in prostate cancer

Conditions: Prostate Cancer

Summary: the aim of this project is to determine whether androgen deprivation therapy (adt) decreases left ventricular function in prostate cancer patients. if found successful, this may lead to improved cardiovascular health via treatment and/or lifestyle interventions in prostate cancer populations.

prostate cancer is the second most common cancer among american men. approximately 1 in 7 men will be diagnosed with prostate cancer during his lifetime. in prostate cancer patients alone, hypotestosteronemia, caused by prostate cancer treatment is associated with visceral adiposity, insulin resistance, metabolic syndrome, decreased high-density lipoprotein, increased low-density lipoprotein, increased triglycerides, loss of muscle mass, erectile disfunction, and a loss of microvascular endothelial function. recently, several population-based studies have reported an association between androgen deprivation therapy and an increased risk of cardiovascular events, that include myocardial infarction and cardiovascular mortality. given this link and the growing evidence that androgen-deprivation therapy adversely affects traditional risk factors, it is essential to better understand the role this type of treatment has on cardiac structure and function. as such, the manifestation of cardiovascular toxicities with prostate cancer treatment will initially be subclinical (left ventricular function changes in asymptomatic individuals) compared to clinical (including coronary symptoms or heart failure) and may develop subacutely (during treatment) or chronically.

Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * (group 1) diagnosed prostate cancer patient/survivor with a history of androgen deprivation therapy treatment * (group 2) diagnosed prostate cancer patient/survivor with no history of androgen deprivation therapy treatment * (group 3) cancer free exclusion criteria: * history of clinical cardiovascular disease (atherosclerotic cardiovascular disease (ascvd) defined by history of acute coronary syndromes, myocardial infarction (mi), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemia attack (tia), or peripheral arterial disease presumed to be of atherosclerotic origin) * not met the above criteria * unable to provide informed consent * history of smoking (within 6 months) or current smoker * major signs or symptoms suggestive of cardiovascular, pulmonary, or metabolic disease. these include pain, discomfort in the chest, neck, jaw, arms or other areas that may result form ischemia; shortness of breath at rest or with mild exertion; dizziness or syncope; orthopnea or paroxysmal nocturnal dyspnea; ankle edema; palpitations or tachycardia; intermittent claudication; known heart murmur; unusual fatigue or shortness of breath with usual activities
effects of an oxymizer® during daytime in patients with pulmonary fibrosis (ipf)

Conditions: Idiopathic Pulmonary Fibrosis

Summary: this study will investigate the effects of a reservoir nasal cannula (oxymizer®) compared to a conventional nasal cannula (cnc) in patients with idiopathic pulmonary fibrosis.

patients will be recruited during a 3-week inpatient pulmonary rehabilitation program. they will perform the following three interventions on consecutive days and will repeat them after a week. during these days the time table for prescribed physical activities and therapies will be kept in a comparable fashion. the following 3 interventions will be performed in randomized order: day a: the patient wears a conventional nasal cannula for 12 h with oxygen flow rate as prescribed during adl day b: the patient wears the oxymizer® with prescribed oxygen flow rate for 12 h during adl day c: the patient wears the oxymizer® with a flow rate reduced by 1l/min in comparison to the prescribed oxygen flow rate, for 12h the following week the same measurements will be repeated. the mean of the corresponding two measures will be calculated for each approach.

Eligibility criteria:
inclusion criteria: * ipf patients with indication for long term oxygen therapy ≥ 2l/min * vc \>30% and \< 70% pred. exclusion criteria: * failure to comply with study process * acute infection

Keywords: oxymizer oxygen conserving device conventional nasal cannula (cnc) idiopathic pulmonary fibrosis
virtual reality for tibial eminence fractures

Conditions: Tibial Fractures

Summary: tibial eminence fracture, a bony avulsion of the anterior cruciate ligament (acl) from its insertion on the intercondylar eminence,1 was first described by poncet in 1875. 2 also known as tibial spine fractures, these injuries occur most commonly in skeletally immature patients between the ages of 8 and 14 years


Eligibility criteria:
inclusion criteria: * age of children from five to nine * children have fracture in tibial eminence exclusion criteria: * children have fracture in tibial eminence grade iii

Keywords: tibial eminence fracture virtual reality
a study to assess the receptor occupancy of cd86 and cd80 in subjects with rheumatoid arthritis initiating abatacept

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to characterize cd86 receptor occupancy in subjects with rheumatoid arthritis (ra) receiving abatacept.


Eligibility criteria:
inclusion criteria: * subject has rheumatoid arthritis (ra), is both abatacept- and belatacept-naïve, and is an eligible candidate to start a course of treatment with abatacept in accordance with the product label * subject is willing and able to comply with study visits and procedures

Keywords: orencia abatacept rheumatoid arthritis infusion
purabond® and pain following resection of oral or oropharyngeal mucosal lesions

Conditions: Pain; Hemorrhage; Hemostatics; Oropharynx; Oral Cavity

Summary: to evaluate the use of purabond® in transoral resections of primary oral or oropharyngeal lesions for diagnostic and therapeutic procedures. patients will be enrolled and randomised to either have purabond® applied to the surgical field or not intra operatively. the primary outcome measure will assess if this intervention significantly reduces acute pain during the 30 day post-operative period alongside other post-operative complication rates and recovery outcomes.

purabond® proof is a prospective, single centre, parallel group randomised controlled trial. transoral approaches in head and neck surgery have become more common given they offer a minimally invasive approach to surgery, thus removing the need for external incisions in the neck. post operative pain and bleeding are clinically important factor that directly impact patient recovery. purabond® is haemostatic agent, classified as a ce marked class iii medical device, that is applied to surgical fields and has been shown to be both safe to use and effective in reducing bleeding. this trial will look to investigate the impact of applying purabond® in oral cavity or oropharyngeal operations on post-operative pain outcomes. patients undergoing a pre-determined set of operations in either the mouth or oropharynx will be randomised to either receive purabond® to the surgical field during the operation or not. this allocation will be random and both treatments are currently used as part of routine standard clinical practice. participants will be asked to monitor and record their pain levels pre and post-operatively by marking their pain level on a continuous scale from 'no pain' to 'the worse possible pain' using the visual analogue scale (vas). patients will be enrolled from a single tertiary university hospital trust in the united kingdom (liverpool university hospitals foundation trust). case notes of all patients will also be analysed and data on patient demographics and post operative outcomes collated. this will be the first trial to look at purabond® use in head and neck surgery with pain being the primary trial outcome.

Eligibility criteria:
inclusion criteria: * patient and disease factors are deemed suitable for transoral surgery under general anaesthetic. * decision to treat with primary transoral resection or local excision biopsy. * written informed consent provided. * clinically suspected or histologically confirmed primary dysplasia or malignancy of the oral cavity or oropharynx or histologically confirmed diagnosis of squamous cell carcinoma in a cervical lymph node of unknown primary. * patient considered fit for surgery. exclusion criteria: * lesions undergoing incisional or punch biopsy only. * surgery with planned primary closure or local/ distant flap reconstruction. * inability to provide written informed consent. * medical contraindication to a general anaesthetic or to purabond® use.
midkine and ace-ang ii induced endothelial injury in sepsis

Conditions: Sepsis

Summary: plasma midkine has reported to be elevated in infection and a regulator of angiotensin-converting enzyme (ace). we aimed to investigate the plasma midkine in septic patients and its association with 28-day mortality and organ function, and also with plasma ace and angiotensin ii.

this study showed that ang ii induced endothelial injury in sepsis patients. midkine has been shown to regulate the renin-angiotensin system and acts in the upstream signaling pathway of angiotensin (ang) ii. the investigators want to access the relationship between midkine level and ace-ang ii induced endothelial injury in sepsis

Eligibility criteria:
the inclusive criteria were adult patients (age \> 18 years-old and \< 80 years-old) diagnosed with sepsis, according the definition of the surviving sepsis campaign (2016) exclusive criteria included: 1. age \ 80 years-old; 2. pregnancy or breastfeeding; 3. malignancy; 4. patients with potentially elevated plasma midkine apart from sepsis including acute myocardial infarction, stroke, limb thrombosis, chronic renal dysfunction (baseline plasma creatine ≥2 mg/dl), autoimmune diseases and alzheimer syndrome; 5. patients deceased or discharge from icu within 24 hours; or, 6. written consents could not be obtained.

Keywords: midkine endothelial injury sepsis angiotensin-converting enzyme angiotensin ii
motivation and methylphenidate

Conditions: Motivation; Apathy; Impulsive Behavior

Summary: the purpose of this study is to evaluate the impact of methylphenidate, a mixed dopaminergic and noradrenergic agent, onto the different components of motivation: decision-making, effort allocation and instrumental learning.


Eligibility criteria:
inclusion criteria: * weight\>= 50kg and \<=90kg * free and informed consent * social security affiliation * no chronic illness * no previous participation to a protocol wth similar tasks * no special legal status (guardianship,trusteeship) * no personnal or familial neurologic or psychiatric background * no contraceptive device for a reproductive woman exclusion criteria: * inability to squeeze a handgrip * smoking * psychoactive substance consumption less than 3 weeks ago * pregnant or breastfeeding woman * hypersensitivity to methylphenidate * hyperthyroidism * cardiovascular or cerebrovascular disease * respiratory, hepatic or renal failure * glaucoma * pheochromocytoma * gluten intolerance or hypersensitivity * galactosemia, glucose malabsorption syndrome, lactase deficit * countraindicated meds (imao, imao-a, orhtosympathomimetics, alcaloids, linezolin, enzymatic inducers, psycho-active drugs)
cross-cultural adaptation and validation of the french version of the exit (experiences of induction tool) (exit)

Conditions: Induction of Labor

Summary: the objective of the study is to cross-culturally adapt and validate the french version of the exit scale: an assessment tool on induction of labor.

favourable agreement was obtained from the authors to adapt the australian moose tool in a cross-cultural manner. none of the co-authors expressed a desire to collaborate on our project. the exit questionnaire is free of rights. the translation of the exit questionnaire into french will be carried out according to the recommended steps of the cross-cultural adaptation process (21, 22, 25): translation of the source version into french by three native french translators, adaptation of the different translations by a group of experts, back translation by two native english speakers, testing with a panel of women who have been triggered for childbirth, in order to arrive at the final version which will be evaluated in a sample of the target population. information about the study will be given to women between day 2 and day 4 postpartum. patients' non-opposition to participate in this study will be collected in the patient's medical record. recruitment of subjects: the study will be proposed to all eligible women who have been induced for their delivery and with an unfavourable cervix in the obstetrics department of the chu estaing, clermont-ferrand. completion of the questionnaire: women will complete the exit self-questionnaire between d2 and d4 post-delivery. the data collection will include additional socio-demographic and clinical information for each woman participating in the study from their medical records. the test-retest involves filling in the exit questionnaire twice at one to two week intervals. the women will be contacted by phone one week after the first exit test, to inform them that a link will be sent by e-mail to complete the exit questionnaire online (on redcap) a second time. they will be called back a second time a week later if the questionnaire is not completed online.

Eligibility criteria:
inclusion criteria: * patients having given birth in the obstetrics department of chu estaing, clermont-ferrand * with an induction of labor * with an unfavorable cervix (bishop score \<6) * on living child(ren) * patients aged 18 years and over, understanding, speaking and reading french * no object to participating in the study. exclusion criteria: * patients induced at first with syntocinon. * patients who do not have an internet connection and an e-mail address. * patients under legal protection (guardianship, tutorship).

Keywords: exit scale induction of labor
shearwave™ elastography of breast lesions in chinese patients

Conditions: Breast Neoplasms

Summary: we aim to determine if adding shearwave elastography to a standard ultrasound breast exam can improve the characterization (classification) of breast lesions.

chinese women are known to have denser breasts than women in western countries. mammography cannot find abnormalities easily in denser breasts, while breast ultrasound is not affected by density. adding elastography, a stiffness measurement, to a breast ultrasound exam should improve the diagnosis of a lesion.

Eligibility criteria:
inclusion criteria: * female * 18 years of age or older * known breast lesion that has not been managed or treated * referred for a breast ultrasound because of a breast mass found on at least one of the following examinations: * physical palpation * mammography * ultrasound exam * mri exclusion criteria: * women who are unwilling or unable to provide informed consent * women with breast implants * women who are pregnant or breastfeeding * women in whom all lesions are diagnostically categorized as bi-rads 0, 1 or 6 * women with previous ipsilateral breast surgery * women with no visible breast mass on ultrasound examination * women with axillary metastatic lymph nodes only * women with foreign body in the breast * women who are not chinese nationality

Keywords: breast lesion ultrasound bi-rads women malignancy
assays for and reversal of new anticoagulants

Conditions: Atrial Fibrillation; Osteoarthritis of the Knee; Osteoarthritis of the Hip

Summary: new anticoagulants are being introduced to replace warfarin. these drugs do not require monitoring and are safer. there is currently no recommended way to reverse these drugs rapidly in the event of undue bleeding or need for emergency surgery. this is a lab study to look at ways to reverse the drugs rapidly

we are developing in vitro assays of measurement of the effect of these drugs on the relevant coagulation pathways in plasma; such assays are not widely established. this will then allow us to test potential reversing agents such as activated factor vii (novo-seven®), or factor viii inhibitor bypassing agent (feiba) for their ability to reverse these anti-coagulants invitro. the aims of this reversal research strategy is to provide a means whereby patients who present with serious bleeding or who need rapid reversal for surgery, for example, can be offered such treatment to allow rapid normalisation of their coagulation system. as part of this developmental programme, we wish to obtain samples from patients receiving rivaroxaban or dabigatran for therapeutic reasons, to test the effect of the respective drug on the relevant coagulation factors and to test in vitro reversibility. the only requirement for the patient is to have an extra 20ml of blood taken at a time when the patient is having other blood tests. there are no risks or experimental procedures planned to be carried out on patients.

Eligibility criteria:
inclusion criteria: * receiving dabigatran for atrial fibrillation * or,for osteoarthritis of the hip or knee receiving rivaroxaban to prevent thromboembolic disease after total hip or knee replacement respectively exclusion criteria: * failure to sign informed consent

Keywords: anticoagulant measurement anticoagulant reversal dabigatran rivaroxaban
efficacy of systane ultra in post menopausal women with dry eye

Conditions: Post Menopausal Dry Eye Subjects

Summary: to evaluate the efficacy of systane ultra in post menopausal women with dry eye.


Eligibility criteria:
inclusion criteria: 1. post-menopausal (menses ceased more than 12 months prior to the start of the study). 2. diagnosed for dry eye exclusion criteria: 1. history of sjögren's syndrome or evidence of chronic dry eye syndrome. confirmed autoimmune connective tissue diseases such as rheumatoid arthritis, fibromyalgia or scleroderma. 2. active and severe blepharitis, rosacea and associated ocular sequelae. 3. has any significant eyelid abnormality affecting lid function.

Keywords: dry eye, post menopausal dry eye
preoperative edema is a significant risk factor for post-hepatectomy complications

Conditions: Patients Who Underwent Hepatectomy for Liver Neoplasms

Summary: aims: the relationship between bioelectrical impedance analysis (bia) results and post-hepatectomy complications is unknown. this study aimed to identify the risk factors for post-hepatectomy complications from the bia results. methods: this prospective, observational cohort study reviewed the data of patients who underwent hepatectomy between march 2018 and december 2022. the patients were matched using the following propensity score covariates: biliary enteric anastomosis and major hepatectomy. risk factors for postoperative complications were investigated in a matched cohort.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of liver neoplasms exclusion criteria: * a body weight loss of \>10% during the 6 months before surgery; the presence of distant metastases; or seriously impaired function of vital organs because of respiratory, renal, or heart disease
gpc3 targeted fluorescence image guided surgery of hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: this study is to evaluate whether intraoperative fluorescence imaging targeting gpc3 can aid improve the surgical accuracy of hepatocellular carcinoma. the main purposes of this study include: ① to raise the detection rate of hepatocellular carcinoma intraoperatively using the novel nir-ii fluorescence molecular imaging and the gpc-3 targeted fluorophore. ② to validate the safety and effectiveness of the designed gpc-3 targeted fluorophore for clinical application.


Eligibility criteria:
inclusion criteria: 1. patients who have been diagnosed with hepatocellular carcinoma. 2. planned to receive hepatectomy. 3. liver function child-pugh a/b. 4. gpc-3 was validated highly expressed preoperatively. 5. aged 18 to 75, and the expected lifetime is longer than 6 months. 6. approved to sign the informed consent. exclusion criteria: 1. allergic to irdye800. 2. enrolled in other trials in the past 3 months. 3. another malignant tumor was found. 4. undesirable function of heart, lung, kidney, or any other organs. 5. unable to tolerate a hepatectomy. 6. the researchers considered inappropriate to be included.
efficacy and safety of mp-424, peginterferon alfa-2b, and ribavirin in patients with chronic hepatitis c who relapsed after previous interferon based therapy

Conditions: Chronic Hepatitis C

Summary: this study will evaluate the efficacy and safety of mp-424 with peginterferon alfa-2b (peg-ifn) and ribavirin (rbv) in patients with (genotype 1) hepatitis c, who relapsed after previous treatment.


Eligibility criteria:
inclusion criteria: * genotype 1, chronic hepatitis c * relapsers (patient who relapsed after previous treatment) * able and willing to follow contraception requirements exclusion criteria: * cirrhosis of the liver or hepatic failure * hepatitis b surface antigen-positive or hiv antibodies-positive * history of, or concurrent hepatocellular carcinoma * history of, or concurrent depression, schizophrenia; or suicide attempt in the past * pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant
response to albuterol delivered through an anti-static valved holding chamber during nocturnal bronchospasm

Conditions: Asthma

Summary: delivery of hfa albuterol through an antistatic valved holding chamber (vhc) will improve bronchodilator response during nocturnal bronchospasm.


Eligibility criteria:
inclusion criteria: * age 18-65 years. * physician diagnosis of asthma. * fev1 60-80% predicted during the day. * fev1 increases ≥ 12 % and to ≥ 80% predicted after 2- 4 puffs of albuterol hfa mdi delivered by antistatic vhc. * no smoking in the previous year and \< 10-pack year history. * no history of severe asthma attacks requiring er visit or hospitalization in the previous three months. exclusion criteria: * patient required a short course of oral steroid in the past 30 days. * any disease that is inadequately controlled or any medication that would worsen asthma or interact with asthma medications. * history of viral respiratory tract infection in the 3 weeks prior to the screening visit. * positive pregnancy test.